The current guidelines of the National Comprehensive Cancer Network recommend the use of ROS1 targeted inhibitors such as crizotinib and entrectinib as the preferred first-line treatment for ROS1 rearrangement-positive NSCLC [19]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.